Mitral Regurgitation - Valvular Heart Disease Guidelines

Valvular Heart Disease

ACC/AHA Valvular Heart Disease - Mitral Regurgitation GUIDELINES Apps brought to you charge courtesy of Guideline Central and Abbott Vascular.

Issue link: https://eguideline.guidelinecentral.com/i/362036

Contents of this Issue

Navigation

Page 21 of 59

Table 17A. Diagnosis and Medical Therapy in Patients With MS Recommendations COR LOE TTE is indicated in patients with signs or symptoms of MS to establish the diagnosis, quantify hemodynamic severity (ΔPmean, MVA, and PA pressure), assess concomitant valvular lesions, and demonstrate valve morpholog y (to determine suitability for mitral commissurotomy). I B TEE should be performed in patients considered for PMBC to assess the presence or absence of le atrial thrombus and to further evaluate the severity of MR. I B Exercise testing with Doppler or invasive hemodynamic assessment is recommended to evaluate the response of the mean mitral gradient and PA pressure in patients with MS when there is a discrepancy between resting Doppler echocardiographic findings and clinical symptoms or signs. I C Anticoagulation (VKA or heparin) is indicated in patients with • MS and AF (paroxysmal, persistent, or permanent), or • MS and a prior embolic event, or • MS and a left atrial thrombus. I B Heart rate control can be beneficial in patients with MS and AF and fast ventricular response. IIa C Heart rate control may be considered for patients with MS in normal sinus rhythm and symptoms associated with exercise. IIb B Mitral Stenosis 20

Articles in this issue

view archives of Mitral Regurgitation - Valvular Heart Disease Guidelines - Valvular Heart Disease